Financial News · Live Terminal

Page 107 of 316

CICC Initiates Quanta Services at Outperform With $872 Price Target

Quanta Services (PWR) has an average rating of overweight and mean price target of $802.91, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$PWR

Research40d ago

UBS Upgrades GE Healthcare Technologies to Neutral From Sell, Adjusts Price Target to $69 From $75

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $78.59, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$GEHC

Research40d ago

Goldman Sachs Upgrades Occidental Petroleum to Neutral From Sell, Adjusts PT to $64 From $57

Occidental Petroleum (OXY) has an average rating of hold and mean price target of $65.29, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$OXY

Research40d ago

Jefferies Downgrades Afcons Infrastructure to Hold from Buy; Adjusts Price Target to INR305 from INR440

BOM:544280NSE:AFCONS

Research40d ago

Maybank Securities Upgrades Thai Beverage Public Company to Buy from Hold; Adjusts Price Target to SG$0.48 from SG$0.43

SGX:Y92

Research40d ago

Research Alert: CFRA Maintains Sell Rating On Shares Of Bio-rad Laboratories Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raised our 12-month target price by $10 to $245, reflecting a 27x multiple on our 2026 EPS estimate, a discount to BIO's three-year historical forward average of 29.5x. We lowered our 2026 EPS estimate to $9.09 from $9.17 and 2027 to $9.80 from $9.87. Though valuations improved somewhat following recent reports of a meaningful stake by activist investor Elliott Management, we think BIO and life sciences tools and services peers continue to navigate a difficult operating environment with pressures in key end markets such as biotech and government/academia. Following BIO's guidance during the Q1 earnings report, we anticipate flat to negative 0.5% sales growth in 2026, along with adjusted operating margin compression to 10.6% from 12.1%. BIO had total cash of $1.6B as of March 31, 2026, supporting the company's negative net debt position (cash exceeds debt).

$BIO

Research40d ago

Research Alert: CFRA Adds Shares Of Astrazeneca Plc To The Total Return Portfolio

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We add shares of AstraZeneca Plc (AZN) to the Total Return portfolio, replacing Medtronic (MDT). In our view, AZN's pipeline, one of the strongest vs. peers, provides a compelling long-term growth story. Late-stage pipeline execution remains robust, with four positive high-value Phase 3 readouts and 14 regulatory approvals achieved so far in 2026. More than 20 Phase 3 trial readouts are expected in 2026, offering multiple near-term catalysts. We think the near-term patent expirations (Farxiga, April 2026, and Soliris, 2027) are well-managed through a robust pipeline and successful lifecycle management. In our view, the solid oncology segment remains a primary growth contributor. AZN has built a strong oncology portfolio, with key drugs like Enhertu, Tagrisso, and Imfinzi that are protected well into the 2030s. Q1 2026 demonstrated sustained momentum, with the oncology segment leading revenue growth (+16% CER, with Enhertu +34% CER based on continued global demand).

$AZN

Research40d ago

Research Alert: Nordson: Q2 Fy 26 Results Top Expectations, Guidance Lifted

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:NDSN delivered strong Q2 FY 26 (Oct.) results, with sales of $741M (+8% Y/Y) and adjusted EPS of $2.86 (+18% Y/Y), beating consensus of $2.85. Organic sales growth of 7% was broad-based across segments, with favorable foreign exchange rates contributing an additional 3%. Order backlog growth of 18% was encouraging, reflecting demand recovery that we see providing stronger visibility and positioning NDSN well for growth. Management raised full-year guidance for both sales and adjusted EPS as demand conditions brighten. Segment performance was mixed, with Industrial Precision Solutions achieving 10% sales growth but experiencing 100-bps EBITDA margin compression to 35%. Advanced Tech Solutions was the standout performer, posting 8% organic growth while expanding EBITDA margins 200 bps to 27%, driven by strong electronics demand. Free cash flow conversion was robust at 113% of adjusted net income, enabling the strategic CapstanAG acquisition to expand precision agriculture capabilities.

$NDSN

Research40d ago

Research Alert: Urban Outfitters Q1 Beats Estimates On Namesake And Free People Strength

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:URBN delivered record Q1 FY 27 results with net sales of $1.48B (+11.4% Y/Y), $20M above estimates, and EPS of $1.30 (+12.1% Y/Y), $0.16 above consensus. Performance was driven by broad-based strength across segments, with Retail sales advancing +8.0% Y/Y and comparable sales increasing +5.6% Y/Y, led by Free People (+9.8% Y/Y) and Urban Outfitters (+9.3% Y/Y). The Subscription segment surged +34.5% Y/Y to $167.3M, while the company repurchased $300M in shares during the quarter. Management expressed confidence in the company's trajectory, citing engaged customers responding to compelling fashion trends. Gross margin contracted 16 bps to 36.6% due to a prior-year gain, though underlying margin improved 20 bps from better markdown discipline. We believe the impressive growth in the subscription business, which is becoming a larger portion of total revenues, supports the investment thesis as URBN continues to diversify beyond traditional retail.

$URBN

Research40d ago

Research Alert: Nvda: Jul-q Guide Well Above Expectations; Returning More Cash To Shareholders

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:NVDA posted Apr-Q revenue of $81.6B (+85% Y/Y, +20% Q/Q), ahead of our $79B expectation, with Data Center revenue of $75.2B (+92%, +21%) representing over 90% of total revenue and $2B above expectations. Non-GAAP EPS of $1.87 (+140% Y/Y) beat the $1.78 consensus, while gross margins remained stable at 75.0%. We view the new reporting framework splitting Data Center into balanced Hyperscale ($37.9B) and ACIE ($37.4B) segments as demonstrating expansion beyond traditional hyperscalers into sovereign AI and enterprise applications. Jul-Q guidance of $91.0B (+/- 2%) came well ahead of our $87B expectation, indicating continued sequential growth momentum. NVDA announced an additional $80B share repurchase authorization and dividend increase to $0.25 per share, signaling confidence in the business trajectory. We continue to anticipate the company will generate over $400B in FCF over the next eight quarters and think returning more cash to shareholders is warranted as top-line growth decelerates over time.

$NVDA

Research40d ago

Research Alert: Intu: Modest Q3 Beat As Turbotax Growth Decelerates; Outlook Mixed

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:INTU posted modest Q3 beats with non-GAAP EPS of $12.80 (+10% Y/Y), beating consensus by $0.23, while revenue of $8.558B (+10% Y/Y) exceeded Street expectations by $20M. Global Business Solutions maintained solid momentum with 15% growth to $3.3B, driven by QuickBooks Online Accounting (+22% Y/Y) from higher prices and customer growth, though Consumer segment decelerated to 8% growth as TurboTax revenue rose just 7% vs. 11% previously. We view the strong Online Ecosystem performance (+19% Y/Y to $2.5B) as encouraging for the core digital strategy. Management raised FY26 revenue guidance to $21.341-21.374B (13%-14% growth) and non-GAAP EPS to $23.80-23.85 (18% growth), though EPS came in below Street expectations. Operating margins compressed to 54.7% from 56.0% Y/Y, while the company announced a 17% workforce reduction to streamline operations. We expect TurboTax Live to reach $2.8B (+36% Y/Y), representing 53% of total TurboTax revenue, demonstrating continued strength in premium offerings.

$INTU

Research40d ago

Research Alert: CFRA Maintains Hold Opinion On Shares Of Canada Goose

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our 12-month price target of CAD15, based on 13x our FY 27 (Mar.) EPS estimate, below the company's three-year average forward P/E multiple of 17.5x. We maintain our FY 27 EPS estimate of CAD1.15 and initiate our FY 28 EPS estimate at CAD1.20. GOOS reported Q4 FY 26 revenue growth of 17.9% to CAD453.3M vs. CAD385M in the year prior, CAD42M above estimates, supported by broad-based strength across channels and geographies. DTC revenue advanced 15.2% to CAD361.7M, with comparable sales growth of 10.0%, marking the fifth consecutive quarter of positive comps. The performance reflected improved conversion rates, enhanced store productivity, and stronger digital engagement. Wholesale revenue surged 54.4% to CAD49.1M primarily due to earlier shipments of the Spring/Summer 2026 collection and increased in-season orders from wholesale partners. Operating income rose 17.8% to CAD64.9M. Q4 FY 26 adjusted diluted EPS improved to CAD0.37 from CAD0.33, CAD0.03 below estimates.

$GOOS

Research40d ago

Research Alert: CFRA Maintains Hold Opinion On Shares Of Canada Goose

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our 12-month price target of USD11, based on 13.1x our FY 27 (Mar.) EPS estimate, below the company's three-year average forward P/E multiple of 17.5x. We maintain our FY 27 EPS estimate of CAD1.15 and initiate our FY 28 EPS estimate at CAD1.20. GOOS reported Q4 FY 26 revenue growth of 17.9% to CAD453.3M vs. CAD385M in the year prior, CAD42M above estimates, supported by broad-based strength across channels and geographies. DTC revenue advanced 15.2% to CAD361.7M, with comparable sales growth of 10.0%, marking the fifth consecutive quarter of positive comps. The performance reflected improved conversion rates, enhanced store productivity, and stronger digital engagement. Wholesale revenue surged 54.4% to CAD49.1M primarily due to earlier shipments of the Spring/Summer 2026 collection and increased in-season orders from wholesale partners. Operating income rose 17.8% to CAD64.9M. Q4 FY 26 adjusted diluted EPS improved to CAD0.37 from CAD0.33, CAD0.03 below estimates.

$GOOS

Research40d ago

Research Alert: CFRA Maintains A Hold Rating On Keysight Technologies, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our target price to $369 from $325, based on 32x our FY 27 EPS estimate, with the multiple reflecting a healthy premium to the historical three-year average of 23x, given our positive outlook on the company's trajectory and recent strong performance. We increase our FY 26 and FY 27 EPS estimates to $10.14 (from $8.87) and $11.53 (from $10.17), led by Q2's impressive margin expansion and favorable business mix shift. Record orders of $2B+ grew 56% Y/Y, significantly outpacing 31% revenue growth and building substantial backlog visibility. Growth is broad-based: CSG revenue grew 35% Y/Y, EISG expanded 24%, and ADG posted record orders due to defense modernization priorities. Operating leverage is translating strong top-line performance into accelerating cash generation (record $472M in FCF). We believe the market has priced in the company's accelerated growth trajectory and enhanced earnings power, with shares up 69% YTD, resulting in a balanced risk/reward outlook.

$KEYS

Research40d ago

Research Alert: Nyt: CFRA Lifts Opinion To Hold From Sell Following Multiple Contraction

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Shares of NYT have fallen 9% since we initiated our Sell on March 23, with next-12-month P/E compressing from 30x to 26x, now below its 27x three-year average. The sell-off was driven by macro headwinds (rising yields, inflation, geopolitics) rather than fundamental deterioration, prompting our upgrade to Hold from Sell. We keep our target price at $76, 27x our unchanged 2026 EPS estimate of $2.83, which remains below the five-year average of 30x. At a recent conference, CEO Levien expressed confidence in reaching 15M subscribers by 2027 vs. 13M today. Operating margins expanded from 7.9% in 2019 to 12.3% in 2025 due to digital bundle adoption. Q1 digital-only subscription revenue grew 16% Y/Y, supporting our estimates. However, we remain at Hold rather than Buy given ongoing print revenue declines (~8% of revenue, declining mid-single digits annually), and AI platform risk, where generative AI could pressure traffic over time, though NYT's premium content and recent licensing deals provide a partial offset.

$NYT

Research40d ago

Research Alert: CFRA Maintains Buy Opinion On Shares Of Analog Devices

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our 12-month target to $435 from $380 on a P/E of 30x our CY 27 EPS view, above the historical average to reflect ADI's more attractive content growth story. After posting better-than-expected Apr-Q results and guidance, we raise our FY 26 EPS estimate to $12.30 from $11.23 and FY 27's to $14.38 from $12.60. We believe that ADI is capitalizing on explosive growth in AI-driven data centers, with its power and optical solutions expected to be the fastest-growing business again in the Jul-Q. ADI's strategic acquisition of Empower Semiconductor and silicon capacitor technology, which is designed to solve power density bottlenecks for AI accelerators, positions ADI as a key partner to hyperscalers. Secular trends in industrial automation, factory onshoring, and electrification provide a durable growth runway for ADI's most profitable segment. Automotive should see improving content growth from AVs and EVs, insulating it from flat auto unit production and offering greater diversification across a host of end-markets.

$ADI

Research40d ago

Research Alert: CFRA Maintains Hold Opinion On Shares Of Dillard's

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $108 to $612, based on 17x our FY 27 EPS estimate and above the company's three-year average of 14.4x. We maintain our FY 27 and FY 28 EPS estimates of $36.00 and $35.00, respectively. We believe Dillard's is deserving of an above-peer multiple due to its above-peer margins and significant capital return program. The company has bought back shares aggressively and has paid large special dividends over the past five years. It operates better than most retailers and has taken a conservative approach to its store count. The company also owns the real estate for over 90% of its stores. We continue to expect DDS's EPS to drop from their elevated levels; however, the company has been able to maintain above $35 through operating efficiencies and share buybacks. We view Dillard's as the best operator in a falling sub-industry and remain neutral.

$DDS

Research40d ago

Research Alert: CFRA Maintains Buy Rating On Shares Of Cvs Health Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $110 from $100, 14.8x our 2026 EPS estimate, above CVS's three-year and five-year average forward multiples of 9.8x and 10.3x, respectively. We raise our 2026 EPS estimate by $0.03 to $7.43 and our 2027 estimate by $0.10 to $8.36. Shares recently yielded 2.8%. While execution risks remain, we think CVS is executing well under its turnaround strategy, supporting our expectations for consistent earnings per share and free cash flow growth through the end of the decade. Though the health insurance operation (Aetna) remains pressured by an environment of elevated medical cost trends, we think Pharmacy & Consumer Wellness appears to be on more stable footing, with the company recently updating long-term segment earnings projections to at least flat vs. the prior view of 5% annual declines. After shedding hundreds of stores as part of its restructuring, the business is expanding to new locations, including smaller, pharmacy-only stores with less general merchandise.

$CVS

Research40d ago

Research Alert: CFRA Upgrades Opinion On Shares Of Tractor Supply Company To Buy From Hold

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We see a buying opportunity with TSCO shares down 38% year-to-date, including a decline of nearly 30% since the company reported weak Q1 results in April. We lower our price target by $9 to $35 (consensus $46) using a forward P/E of 15.9x, a deep discount to the three-year historical average of 23.7x and the five-year average of 25.2x on normalized earnings. Due to lower demand, we previously reduced our revenue projections to $16.4B in 2026 and $17.0B in 2027, compared with consensus estimates of $16.2B and $17.1B, respectively. Our EPS estimates are unchanged at $2.20 in FY 26 and $2.46 in FY 27 (consensus: $2.13, $2.31). We view the weakness as cyclical, not secular. TSCO faces material operating headwinds from declining transaction counts, structural challenges, and persistent tariff pressures. TSCO maintains a solid balance sheet, strong new store productivity (65%-70% range), and resilient performance in core C.U.E. categories, providing a basis for potential rebound if consumer demand stabilizes.

$TSCO

Research40d ago

Research Alert: CFRA Maintains Hold Opinion On Shares Of Dominion Energy, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We see more favorable risk/reward for D vs. NEE. For now, our base case assumes the merger falters on regulatory hurdles. In this situation, we don't expect D shares to fall to the ~$62 pre-announcement price due to the $4.83B breakup fee D will receive if the deal falls through. In the simplest situation, the cash influx equates to a ~$5.50 per share valuation boost, where we see a rough valuation floor around $67. D could deploy the breakup fee to reduce debt, lower future financing needs for its capital plan, pursue bolt-on acquisitions, or return capital to shareholders. Based on May 19 closing and the .8138 exchange ratio, the market is pricing in a ~7.6% risk premium for deal failure. We expect that to narrow on positive developments. Currently, we see a valuation ceiling of ~$86 based on our $106 NEE price target. We lift our 12-month target by $8 to $72, 20.0x our next-12-month EPS estimate of $3.58. Our 2026 and 2027 EPS views are kept at $3.59 and $3.81 respectively and reflect standalone D.

Showing 2121-2140 of 6315